fda glp-1 warning letters october 2025 news compounding Pharmacovigilance Assessment of Compounded GLP-1 Receptor Agonists: Insights From the FDA Adverse FDA unleashes warning letters to – Trends In FDA FY 2025

While type 1 often manifests as an autoimmune insulin deficiency during childhood, T2DM predominantly develops throughout life

Key Takeaways Most doctors advise against using GLP-1 medications while breastfeeding due to limited human safety data

Jayne Hornung, chief clinical officer at Managed Markets Insight and Technology, suggests initial pricing of oral GLP-1s for weight loss could be reminiscent of the early days of anti-CGRP medications for migraines when the first oral CGRP came to market in 2019, the pricing still remained high

As patients are often seen only shortly before surgery, this policy could lead to unnecessary postponement of surgery

GLP-1 receptor agonists are increasingly favored for their ability to promote sustained weight reduction, improve glycemic control, and deliver cardiovascular benefitsmaking them superior to many legacy obesity treatments

doi: 10.1016/j.bcp.2023.115875 22